Use of disease‐modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey
Open Access
- 19 October 2011
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (2), 184-189
- https://doi.org/10.1002/acr.20674
Abstract
Objective Disease‐modifying antirheumatic drugs (DMARDs) are recommended for virtually all patients with rheumatoid arthritis (RA). We investigated the use of DMARDs in patients with RA in a nationally representative sample of visits to US physicians in the National Ambulatory Care Medical Survey (NAMCS). Methods We analyzed the NAMCS visit data from 1996 through 2007 if the physician noted a diagnosis of RA. DMARD utilization was based on the medications listed by the physician. We used generalized linear models to examine the adjusted associations between DMARD use and potential predictors. Results Of the 859 visits with a diagnosis code of RA identified over the study period, 404 visits (47%; 95% confidence interval [95% CI] 44–50%) had an associated DMARD. The percentage of RA visits with DMARDs increased slightly over the 12 years (P = 0.048), with biologic DMARDs increasing to 20% of visits after their introduction (P for trend <0.001). In fully adjusted models, African American race was associated with a 30% reduction in DMARD prescribing (risk ratio [RR] 0.70, 95% CI 0.48–1.00). A visit to a rheumatologist was the strongest correlate of DMARD prescribing (RR 2.33, 95% CI 1.89–2.86). Among visits to nonrheumatologists, African Americans were significantly less likely than whites to receive a DMARD (RR 0.39, 95% CI 0.17–0.92), but not among visits with rheumatologists (RR 0.81, 95% CI 0.52–1.27). Conclusion In the NAMCS, most visits coded with RA did not have an associated DMARD prescription. African Americans were less likely to receive DMARDs than whites, particularly when visiting nonrheumatologists.Keywords
This publication has 21 references indexed in Scilit:
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care PlansPublished by American Medical Association (AMA) ,2011
- Quality care in seniors with new‐onset rheumatoid arthritis: A Canadian perspectiveArthritis Care & Research, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals Of The Rheumatic Diseases, 2010
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Treatment of older adult patients diagnosed with rheumatoid arthritis: Improved but not optimalArthritis Care & Research, 2007
- Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyCurrent Medical Research and Opinion, 2005
- The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research DatabaseRheumatology, 2005
- Epidemiology of Total Knee Replacement in the United States Medicare PopulationPublished by Ovid Technologies (Wolters Kluwer Health) ,2005
- Gaps in care for rheumatoid arthritis: A population studyArthritis Care & Research, 2005
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002